舒肝宁注射液联合还原型谷胱甘肽对原发性肝癌经导管动脉化疗栓塞术后患者肝功能和血清T淋巴细胞水平的影响

摘要

目的 分析原发性肝癌经导管动脉化疗栓塞术(TACE)术后患者应用舒肝宁注射液联合还原型谷胱甘肽对其肝功能和血清T淋巴细胞水平的影响.方法 选取2016年3月至2017年7月在吉林大学第一医院采用TACE治疗的120例原发性肝癌患者作为研究对象.根据随机数字表法分为对照组和观察组,每组60例.对照组TACE术后采用还原型谷胱甘肽治疗,观察组TACE术后采用舒肝宁注射液联合还原型谷胱甘肽治疗.观察并对比2组患者治疗前后肝功能指标和血清T淋巴细胞水平变化.结果 治疗前,2组患者的丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、总胆红素和直接胆红素(DBIL)水平差异均无统计学意义(均P＞0.05);治疗后,观察组ALT、AST、总胆红素和DBIL水平均明显低于对照组[(53±8)U/L比(69±11)U/L、(53±9) U/L比(68±11)U/L、(19±4) μmol/L比(23 ±4) μmol/L、(7±3) μmol/L比(9±4) μmol/L],差异均有统计学意义(均P＜0.05).治疗前,2组患者的CD4+T/CD8+T比值差异无统计学意义(P＞0.05);治疗后,观察组CD4+T/CD8+T比值明显高于对照组[(1.36±0.11)比(1.03±0.14)],差异有统计学意义(P＜0.05).结论 舒肝宁注射液联合还原型谷胱甘肽治疗原发性肝癌TACE术后患者效果明显,能有效改善患者的肝功能,调节患者的血清T淋巴细胞水平,增强机体免疫功能,减轻肝脏损伤,利于患者术后恢复.%Objective To analyze the effect of Shuganning injection combined with reduced glutathione on liver function and serum T lymphocytes in primary liver cancer patients after transcatheter arterial chemoembolization (TACE).Methods A total of 120 patients with primary liver cancer who had TACE from March 2016 to July 2017 were enrolled in the First Hospital of Jilin University.The patients were randomly divided into control group and observation group,with 60 cases in each group.The control group was treated with reduced glutathione.The observation group was treated with Shuganning injection combined with reduced glutathione.Liver function indexes and serum T lymphocytes were analyzed.Results Levels of alanine aminotransferase (ALT),aspartate aminotransferase(AST),total bilirubin and direct bilirubin (DBIL) showed no significant differences between groups before treatment(P ＞ 0.05).After treatment,ALT,AST,total bilirubin and DBIL in the observation group were significantly lower than those in the control group [(53 ± 8) U/L vs (69 ± 11) U/L,(53 ± 9) U/L vs (68 ±11) U/L,(19 ±4) μmol/L vs (23 ±4) μmol/L,(7 ±3) μmol/L vs (9 ±4) μmol/L] (P ＜0.05).CD4+ T/CD8+ T ratio showed no significant difference between groups before treatment(P ＞ 0.05).After treatment,CD4+ T/CD8+ T ratio in the observation group was significantly higher than that in the control group [(1.36 ± 0.11) vs (1.03 ±0.14)] (P ＜ 0.05).Conclusion Shuganning injection combined with reduced glutathione treating post-TACE primary liver cancer patients can effectively improve liver function and T lymphocyte balance.